

Perspective

Open Access



Microbial influence on blood pressure: unraveling the complex relationship for health insights

Alexander Machado Cardoso 

Department of Biology, Rio de Janeiro State University, Rio de Janeiro 23070200, Brazil.

Correspondence to: Prof. Alexander Machado Cardoso, Department of Biology, Rio de Janeiro State University, Avenida Manuel Caldeira de Alvarenga - 1203, Rio de Janeiro 23070200, Brazil. E-mail: amcardosopf@yahoo.com.br

How to cite this article: Cardoso AM. Microbial influence on blood pressure: unraveling the complex relationship for health insights. *Microbiome Res Rep* 2024;3:22. <https://dx.doi.org/10.20517/mrr.2023.73>

Received: 9 Dec 2023 **First Decision:** 5 Feb 2024 **Revised:** 29 Feb 2024 **Accepted:** 13 Mar 2024 **Published:** 18 Mar 2024

Academic Editor: Colin Buttmer **Copy Editor:** Dong-Li Li **Production Editor:** Dong-Li Li

Abstract

Hypertension, a critical global health concern, is characterized by persistent high blood pressure and is a major cause of cardiovascular events. This perspective explores the multifaceted implications of hypertension, its association with cardiovascular diseases, and the emerging role of the gut microbiota. The gut microbiota, a dynamic community in the gastrointestinal tract, plays a pivotal role in hypertension by influencing blood pressure through the generation of antioxidant, anti-inflammatory, and short-chain fatty acids metabolites, and the conversion of nitrates into nitric oxide. Antihypertensive medications interact with the gut microbiota, impacting drug pharmacokinetics and efficacy. Prebiotics and probiotics present promising avenues for hypertension management, with prebiotics modulating blood pressure through lipid and cholesterol modulation, and probiotics exhibiting a general beneficial effect. Personalized choices based on individual factors are crucial for optimizing prebiotic and probiotic interventions. In conclusion, the gut microbiota's intricate influence on blood pressure regulation offers innovative perspectives in hypertension therapeutics, with targeted strategies proving valuable for holistic blood pressure management and health promotion.

Keywords: Cardiovascular risk, gut microbiota, hypertension, lactobacillus, machine learning, microbiome-host interactions



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



INTRODUCTION

Hypertension is a multifactorial disease with genetic and environmental factors contributing to its development. The pathophysiology of hypertension is complex and involves a variety of physiological mechanisms, including salt intake, obesity and insulin resistance, the renin-angiotensin system, and the sympathetic nervous system^[1]. Other factors that have been evaluated include genetics, endothelial dysfunction, low birth weight and intrauterine nutrition, and neurovascular anomalies^[2]. Environmental factors such as cold temperature, high altitude, loud noises, stress, and ambient air pollutants can also significantly increase arterial blood pressure (BP), and chronic exposures may be capable of promoting the development of sustained hypertension^[3].

Being a major risk factor for cardiovascular events and the primary cause of adult mortality, hypertension is a serious global public health concern that is characterized by persistently high BP. It has been acknowledged as the primary risk factor, or as one of the most powerful risk factors, for the development of a variety of diseases that are acquired over the course of a person's lifetime. These include a range of illnesses such as heart disease, heart arrhythmias, valvular heart diseases, cerebral stroke, and kidney failure^[4]. Due to the widespread impact of hypertension, multifaceted approaches to its prevention and treatment are imperative as it plays a critical role in the development of numerous diseases^[4,5].

Extensive cohort studies have conclusively demonstrated that high BP is a significant risk factor for chronic kidney disease, atrial fibrillation, and heart failure^[6]. The most important modifiable risk factor associated with early cardiovascular disease, when considering population attributable risk, is hypertension. A thorough systematic review and meta-analysis showed a progressive and graded relationship between various BP categories and young adults' risk of cardiovascular events. Interestingly, this risk showed a progressive increase over different BP increments. In the context of public health, these findings highlight the critical role that BP management plays in reducing the risk of cardiovascular morbidity and the significance of focused interventions^[3].

Recent studies have highlighted the revolutionary potential of high-throughput sequencing and integrative multi-omics approaches in deciphering the complex mechanisms underlying hypertension. Thanks to the power of bioinformatics and high-throughput technologies, an extensive global genome exploration has been made possible, revealing dysregulated genes that are closely associated with hypertension^[7]. Beyond genomics, novel insights into the molecular basis of hypertension have been provided by postgenomic biomarkers derived from metagenomics, transcriptomics, proteomics, glycomics, and lipidomics^[8].

In order to comprehend the intricate interplay between internal and external risk variables that underpin the pathogenesis of hypertension, multi-omics analyses across the spectrum of continuous variations in BP values have to be incorporated^[9]. These studies have the potential to identify risk factors, clarify the complex molecular landscape of hypertension, and track treatment outcomes. It is crucial to recognize that there are inherent computational and practical challenges with performing an integrative analysis of omics data. As of right now, this method is still not widely used in hypertension research^[10]. The combination of high-throughput sequencing and multi-omics approaches is expected to make a substantial contribution to our understanding of hypertension at the molecular level as these challenges are rigorously addressed and methodologies progress. This development could lead to the implementation of precision medicine in the treatment of hypertension and more focused therapeutic approaches^[11].

The objective of this perspective is to provide insight into whether beneficial microbes, which are microorganisms that have positive effects on host health, could effectively contribute to enhancing the

management of high BP. These microorganisms are typically found in the gastrointestinal tract, particularly in the colon, where they contribute to various physiological processes and help maintain homeostasis^[12]. The microbiome refers to the diverse community of microorganisms that interact with their hosts in a range of relationships, including symbiotic, commensal, and pathogenic. Symbiosis, specifically, involves mutually beneficial exchanges between the host and microbiota, contributing to the maintenance of homeostasis and overall health^[13]. The examination of microbial communities, their interactions, evolution, and the identification of novel molecular pathways in hypertension can be tackled through the application of computational predictive methods and functional genomics^[14]. In an effort to understand the mechanistic relationships between the microbiome (the complete collection of genetic materials derived from all the microorganisms inhabiting a given environment) and the host, computational biology and machine learning techniques have been developed. The methodologies encompass the identification of novel molecular mechanisms and the profiling of heterogeneous datasets that document changes in the microbiome and host responses at the community level^[15].

These methods have been used to examine and deduce the interactions between host molecular components and the microbiota in a variety of disease contexts. Evidence of possible connections between the gut microbiota (GM) and BP in the setting of hypertension has been found, and the magnitude of these interactions has been studied^[16]. Additionally, despite having similar GM profiles, a study that integrated microbiome pathway analysis and machine learning found differences in microbial gene pathways between participants with hypertension and those with normotension^[17,18]. The downregulation of the nitrite transporter and salt transport system genes in hypertension individuals was especially noteworthy. Moreover, a significant increase in acetate-CoA ligase, an enzyme involved in the production of butyrate that can lower BP in experimental hypertension, was observed^[18]. Consequently, functional genomics and computational predictive approaches can offer important new perspectives on the investigation into microbial communities and their connection to hypertension^[17].

In addition to its pivotal role in BP regulation, the GM exerts multifaceted effects on host health and disease, such as intestinal vascularization and gut barrier regulation^[19]. These effects span diverse physiological processes, including immune homeostasis, physiological remodeling, and the maintenance of gut barrier integrity. The intricate interplay between the microbiota and the host extends beyond mere symbiosis, encompassing mechanisms that discriminate between homeostasis and dysbiosis. This continuous interaction exerts profound impacts on the host's physiology and pathology. To provide a comprehensive overview of gut microbial effects on host health and disease, it is important to elucidate not only the specific relationship between the microbiota and BP regulation but also its broader implications for overall health.

GUT MICROBIOTA CONTROLS BLOOD PRESSURE

The gastrointestinal tract is colonized by a complex and constantly evolving population of microorganisms known as the GM. It has co-evolved with the host and is composed of bacteria, archaea, and eukaryotes, including viruses that infect prokaryotes (bacteriophages) and eukaryotic viruses that infect human cells^[20]. This dynamic community significantly influences host physiology during both normal physiological states (homeostasis) and pathological conditions (illness)^[21]. For example, it has been demonstrated that the proportion of the bacterial species Firmicutes to Bacteroidetes affects both health and disease^[22]. The microbiota in the gut plays an essential role in the immune system and metabolism, as well as in the fermentation of substrates that are not digestible, such as dietary fibers^[23]. Several variables, including host genetics, environment, drugs, and diet, affect the GM's composition. Studies have indicated that some chronic gastrointestinal diseases may be influenced by the GM, and that modifying it may be a useful therapeutic strategy to address these disorders^[24].

Additionally, it is believed that the GM shapes the composition and diversity of intestinal microbiota by participating in the breakdown of dietary fiber and the production of short-chain fatty acids (SCFAs)^[25]. Studies suggest that SCFAs, such as acetate, propionate, and butyrate, derived from GM play a significant role in BP regulation through various mechanisms and are essential in cardiovascular homeostasis. SCFAs interact with some receptors, influencing vasodilation and neural feedback in the gut, ultimately affecting BP levels^[26,27]. Research indicates that SCFAs can activate different receptors, leading to complex and diverse effects on BP regulation. For instance, SCFAs binding to GPR41 can induce vasodilation and lower BP, while binding to Olfr78 may increase BP levels^[28]. Moreover, SCFAs have been linked to the expression of genes involved in BP regulation, highlighting their potential as a target for novel prevention and treatment methods for hypertension^[26]. Besides SCFAs, other microbial metabolites that have been investigated for their effects on BP regulation include trimethylamine-N-oxide (TMAO) and bile acids (BAs). TMAO has been shown to influence BP, with studies demonstrating its BP-lowering effects in patients with resistant hypertension^[29]. Additionally, gut bacteria and their metabolites may affect BP variability through systemic mechanisms outside the intestine^[8]. BAs have been implicated in BP regulation. Serum total bile acid (TBA) has been associated with new-onset hypertension during pregnancy, where high TBA levels were positively related to systolic and diastolic BP, and proteinuria^[30]. Furthermore, some BAs have vasodilatory effects; for instance, taurocholic acid has been shown to induce vasodilation in mesenteric and aortic rings^[31].

In general, the human GM plays a vital role in various physiological processes, and research on this topic is ongoing. Recent studies have brought to light the importance of the GM in the etiology and development of hypertension. Dysbiosis of the GM is linked to a reduction in the expression of tight junction proteins, a decrease in the quantity of goblet cells, a breakdown of the gut epithelial barrier, and a decrease in mucus in the intestinal lumen, suggesting that it might contribute to the development of hypertension^[32]. Hypertension has been correlated with GM dysbiosis, which includes an increased abundance of Gram-negative microbiota^[33]. Through a variety of mechanisms, the GM can control BP by including host-induced modifications to microbiome-associated gene pathways, such as using G protein-coupled receptors to activate many downstream signaling pathways^[26]. Both in humans and animals, the relationship between GM and hypertension has been noted, and microbial genera that influence BP have been identified^[34].

Animal studies have indicated that the GM plays an important role in the regulation of hypertension. For instance, a study discovered that raised BP was linked to the prevalence of Firmicutes and Bacteroidetes in gut by using several hypertension models, including rats that were spontaneously hypertensive and Dahl salt-sensitive^[35]. Numerous large-cohort investigations have revealed inconsistent microbiological indicators, and the connection between GM and hypertension still has to be clarified^[36]. However, some studies have identified specific microbes and metabolic pathways that may help explain the protective effect of probiotics (live microorganisms, typically bacteria or yeast, that confer health benefits) in treating hypertension; in fact, the metagenomic analysis revealed that the increased *Lawsonia* and *Pyrolobus*, and reduced *Alistipes* and *Alloprevotella* levels were tightly correlated with lowered BP, suggesting that these bacteria could affect BP by changing steroid hormone levels^[37].

It has been determined that several microbial genera influence BP. Blood pressure is correlated with increases in *Lactobacillus*, *Roseburia*, *Coprococcus*, *Akkermansia*, and *Bifidobacterium*, and inversely correlated with increases in *Streptococcus*, *Blautia*, and *Prevotella*^[34]. Furthermore, several bacteria can stimulate the synthesis of trimethylamine-N-oxide (TMAO), a metabolite that is currently the subject of extensive research in the field of hypertension^[38]. Specifically, *Enterobacteriaceae* have been shown to

promote the growth of bacteria that produce trimethylamine (TMA) from TMAO, while certain lactic acid bacteria also exhibit increased lactate production when grown in the presence of TMAO^[39]. Additionally, other bacterial strains like *Anaerococcus hydrogenalis*, *Clostridium asparagiforme*, *Clostridium hathewayi*, and *Clostridium sporogenes* have been linked to TMA generation^[40]. The GM plays a critical role in TMAO metabolism, and understanding how bacterial communities influence TMAO levels could inform new therapeutic approaches to manage conditions such as hypertension and cardiovascular disease^[41,42].

WHAT IMPACT DOES THE GUT MICROBIOTA HAVE ON BLOOD PRESSURE?

Numerous studies using germ-free mouse models have provided compelling evidence of the causal relationship between the GM and BP regulation^[43,44]. These investigations have demonstrated that the GM has an essential role in BP control and that altering the microbiota may be a promising treatment for hypertension. Utilizing gnotobiotic, or germ-free, mice has proven crucial in this field. The mice exhibit blunted responses to angiotensin II and experience elevated blood pressure after receiving fecal transplants from hypertension patients instead of normotensive donors. In both genetic and pharmacological models, restoration of normal microbiota reduces and prevents the development of hypertension, and experimental hypertension is typically associated with alterations in the composition of the GM^[45]. Comparing germ-free rats to their conventionalized counterparts, the lack of microbiota led to relative hypotension, indicating that GM is essential for BP regulation. When microbiota was introduced to germ-free rats, both BP and vascular contractility returned, suggesting that microbiota might influence BP via a vascular-dependent mechanism^[46].

It remains to be seen how the GM influences BP. Global knowledge about the gut microbiome's role in hypertension may offer crucial insights into its prevention. Recently, it was demonstrated that the human breast milk-derived bacteria, administered orally, could lower BP and alter metabolites in a mouse model of elevated BP induced by high fructose, suggesting a potential therapeutic approach^[37].

The interplay between the gut microbiome and the immune system is complex and dynamic, and it has significant implications for health and disease, including the regulation of inflammatory responses and the maintenance of immune homeostasis^[47]. Studies have shown that anti-inflammatory and antioxidant properties can help regulate BP. A disruption in the equilibrium between oxidants and antioxidants is known as oxidative stress, and it has been connected to the emergence of endothelial dysfunction, inflammation, and heightened vascular contractility, which in turn leads to the remodeling of cardiovascular tissue^[48]. Antioxidants and microbial components, such as carotenoids, polyphenols, vitamins, and sterols, have been shown to restore the proper functioning of vessels and reverse the harmful effects of free radicals. Additionally, flavonoids have been reported to have vasodilatory and antihypertensive effects^[49]. The phytochemical indole-3-carbinol, which is obtained from cruciferous vegetables, has demonstrated anti-inflammatory, antioxidant, antihypertensive, and antiarrhythmic properties^[50]. Anti-inflammatory and antioxidant properties of some microbial metabolites may help regulate BP and have great potential for therapeutic treatments^[51]. For instance, SCFAs like acetate and butyrate have been observed to have anti-inflammatory effects on myeloid and intestinal epithelial cells, potentially benefitting BP regulation^[52]. Additionally, SCFA-producing bacteria like *Faecalibacterium* and *Coprococcus* have been associated with lower BP and better mental health outcomes^[53].

It is interesting to note that some GM plays a crucial role in metabolizing certain nutrients, such as nitrates from vegetables, and converting them into nitric oxide, a vasodilator molecule that helps relax blood vessels and regulate BP. This process involves the microbial reduction of nitrates to nitrites and further to nitric oxide, which has been shown to contribute to the maintenance of cardiovascular health and the regulation

of BP^[38]. The microbially-derived NO can cross the epithelial barriers, reaching the portal vein and eventually entering the systemic circulation^[54]. The production of nitric oxide from dietary nitrates by the GM represents an important link between diet, the gut microbiome, and cardiovascular function, highlighting the potential impact of microbial metabolism on human health^[8].

The gut microbiome can also play a significant role in the metabolism, pharmacokinetics, and efficacy of antihypertensive medications. The GM can influence the pharmacokinetics of antihypertensive drugs, affecting their absorption, distribution, and elimination. This can lead to changes in drug concentrations and may impact the overall effectiveness of the medication^[55]. Understanding these interactions is crucial for optimizing the treatment of hypertension and addressing the challenges associated with drug resistance. Antihypertensive medications can interact with the gut microbiome, which may affect drug pharmacokinetics and the efficacy of BP-lowering drugs^[56]. Resistant hypertension is a condition where BP remains high despite taking at least three different antihypertensive drugs at optimal doses. Understanding the interactions between different medications and lifestyle factors is crucial for optimizing the treatment of hypertension and addressing the challenges associated with drug resistance^[57].

The GM plays a role in the metabolism of antihypertensive drugs, which can contribute to drug resistance^[58]. For example, antihypertensive drugs such as amlodipine and nifedipine can be metabolized by gut microbial enzymes, influencing drug absorption, and leading to changes in their pharmacokinetic parameters^[59]. The GM has been shown to be involved in the development of antihypertensive drug resistance, which can lead to a reduced response to antihypertensive medications^[58]. Depletion of the GM, achieved through antibiotic treatment, has been shown in a patient to enhance the BP-lowering effect of certain antihypertensive drugs, suggesting that the GM plays a significant role in their efficacy^[60].

Antihypertensive drugs such as losartan, valsartan, and telmisartan can be transformed by GM in the *in vitro* setting, suggesting potential interactions with the gut microbiome. However, the specific metabolites generated and their effects on the efficacy of the drugs are not clear and may represent secondary effects due to the complex interplay between antihypertensive agents and GM. Interestingly, the angiotensin receptor antagonist losartan reduced gut dysbiosis and improved gut integrity in an experimental model^[61]. Some medications may affect gut microbiome composition and gut epithelial barrier, as endothelial dysfunction and attenuation of BP may be increased in response to angiotensin^[62]. Captopril (angiotensin-converting enzyme inhibitor) reshaped the gut microbiome composition, and following its withdrawal, there was a noticeable alteration in microbial composition, with *Parabacteroides*, *Mucispirillum*, and *Allobaculum* being the most prominently increased genera^[63]. Additionally, the medication reduced gut inflammation and permeability. The metoprolol (beta-blocker) hypertension treatment might affect BP by changing levels of gut microbiome-derived metabolites in patients with hypertension^[64], and the medication enalapril might be involved in BP regulation by changing gut microbiome composition and reducing blood TMAO levels in an experimental model^[65].

A recent study has shown how complex and multifaceted the relationship is between BP, antihypertensive drugs, and GM^[55]. It is expected that a significant percentage (more than 10%) of hypertension patients show resistance to standard treatments^[66]. The pathophysiological processes and etiology of resistant hypertension are still not well understood. Thus, additional investigation is necessary to have a more profound comprehension of these processes and may reveal possible therapeutic consequences resulting from these intricate relationships.

PREBIOTIC AND PROBIOTIC INTERVENTIONS

Many studies have highlighted the importance of prebiotics, which are components that selectively promote the proliferation and/or activity of specific bacteria in the gut, improving host health^[67]. According to recent studies, prebiotics may have a role in preventing and/or lowering hypertension based on experimental findings. Prebiotics have been shown to reduce the incidence of hypertension through a variety of strategies, but one particularly noteworthy one is their impact on blood lipid and cholesterol levels, which are both strongly associated with hypertensive disorders^[68]. A possible mechanism for the lipid and cholesterol-lowering benefits of prebiotics is the synthesis of SCFAs. This interaction highlights one possible way that prebiotics support the regulation of BP. Prebiotics have been shown to be effective in lowering the risk of hypertension by aiding in the gastrointestinal tract's ability to absorb minerals such as calcium^[69]. This comprehensive strategy highlights the potential of prebiotics to affect multiple physiological systems linked to BP management in addition to altering GM. Furthermore, new studies demonstrate how a high-fiber prebiotic supplement can lower BP in people with hypertension due to changes in the makeup of gut bacteria^[68].

Probiotics are living microorganisms that provide health advantages to the host when ingested in appropriate amounts^[70]. Several probiotic bacterial strains are ingested for their health benefits. Examples of such strains include those belonging to the genera *Lactobacillus*, *Bifidobacterium*, *Saccharomyces*, *Enterococcus*, *Streptococcus*, *Pediococcus*, *Leuconostoc*, and *Bacillus*. According to various studies, incorporating probiotics into diet could potentially lead to a reduction in BP, particularly among individuals with initially elevated levels^[71]. Probiotic supplements dramatically lowered systolic and diastolic BP, according to other studies^[72], notably in individuals with hypertension and type 2 diabetes. In addition, it has been discovered that two probiotic strains, *Lactobacillus rhamnosus* and *Bifidobacterium lactis*, which are found in foods like cheese and yogurt, may help decrease BP^[37]. Utilizing both probiotics and prebiotics together offers a synergistic approach to optimally modify GM and potentially exert greater BP-reducing effects than either alone. These results suggest that prebiotics and probiotics may help lower BP, but more studies are needed to confirm their effectiveness. Remarkably, patients' prebiotic and probiotic choices should be customized according to their unique circumstances, including age, sex, ethnicity, food preferences, way of life, and amount of physical activity they engage in each day^[73,74].

CONCLUSION

The microbiota plays a fundamental role in controlling hypertension, exerting a direct influence on various aspects of the cardiovascular system and health. In addition to traditional factors such as diet and lifestyle, the microbial community in the gastrointestinal tract has a notable impact on BP regulation. Recent studies have revealed the complex interaction between the microbiota and BP control. Beneficial bacteria in the gut produce metabolites, such as SCFAs, that play a crucial role in hypertension control. These compounds have anti-inflammatory and antioxidant properties, helping regulate BP. The GM also plays a role in metabolizing certain nutrients, such as nitrates from vegetables, converting them into nitric oxide, a vasodilator molecule that helps relax blood vessels and regulate BP. Furthermore, the GM influences the immune system by modulating systemic inflammatory responses. Chronic inflammation is associated with the development of hypertension, and the microbiota plays a key role in regulating this inflammatory state. Therefore, understanding the importance of the microbiota in hypertension control offers an innovative perspective on the therapeutic and preventive approach to this condition. Targeted strategies to promote a healthy microbiota, through dietary interventions, probiotics, and prebiotics, can become valuable tools in managing BP and promoting health in a holistic manner.

DECLARATIONS

Acknowledgments

The author thanks the technical support and insightful discussions of UERJ, PUC, and FIOCRUZ staff.

Authors' contributions

The author contributed solely to the article.

Availability of data and materials

Not applicable.

Financial support and sponsorship

None.

Conflicts of interest

The author declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2024.

REFERENCES

1. Leow MK. Environmental origins of hypertension: phylogeny, ontogeny and epigenetics. *Hypertens Res* 2015;38:299-307. DOI PubMed
2. Beevers G, Lip GY, O'Brien E. ABC of hypertension: the pathophysiology of hypertension. *BMJ* 2001;322:912-6. DOI PubMed PMC
3. Brook RD. The environment and blood pressure. *Cardiol Clin* 2017;35:213-21. DOI PubMed
4. Kjeldsen SE. Hypertension and cardiovascular risk: general aspects. *Pharmacol Res* 2018;129:95-9. DOI PubMed
5. Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. *Hypertension* 2020;75:285-92. DOI PubMed PMC
6. Roth GA, Mensah GA, Johnson CO, et al; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. *J Am Coll Cardiol* 2020;76:2982-3021. DOI PubMed PMC
7. Kamali Z, Keaton JM, Haghjooy Javanmard S, et al. Large-scale multi-omics studies provide new insights into blood pressure regulation. *Int J Mol Sci* 2022;23:7557. DOI PubMed PMC
8. Dinakis E, Nakai M, Gill P, et al. Association between the gut microbiome and their metabolites with human blood pressure variability. *Hypertension* 2022;79:1690-701. DOI PubMed
9. Adua E. Decoding the mechanism of hypertension through multiomics profiling. *J Hum Hypertens* 2023;37:253-64. DOI PubMed PMC
10. Currie G, Delles C. The future of "omics" in hypertension. *Can J Cardiol* 2017;33:601-10. DOI PubMed PMC
11. Nitzan M, Nitzan I. Feasibility of precision medicine in hypertension management-scope and technological aspects. *J Pers Med* 2022;12:1861. DOI PubMed PMC
12. Linares DM, Ross P, Stanton C. Beneficial microbes: the pharmacy in the gut. *Bioengineered* 2016;7:11-20. DOI PubMed PMC
13. Eloe-Fadrosh EA, Rasko DA. The human microbiome: from symbiosis to pathogenesis. *Annu Rev Med* 2013;64:145-63. DOI PubMed PMC
14. Sudhakar P, Machiels K, Verstockt B, Korcesmaros T, Vermeire S. Computational biology and machine learning approaches to understand mechanistic microbiome-host interactions. *Front Microbiol* 2021;12:618856. DOI PubMed PMC
15. Grazioli F, Siarheyev R, Alqassem I, Henschel A, Pileggi G, Meiser A. Microbiome-based disease prediction with multimodal variational information bottlenecks. *PLoS Comput Biol* 2022;18:e1010050. DOI PubMed PMC
16. Palmu J, Lahti L, Niiranen T. Targeting gut microbiota to treat hypertension: a systematic review. *Int J Environ Res Public Health*

- 2021;18:1248. DOI PubMed PMC
17. Aryal S, Manandhar I, Mei X, et al. Combating hypertension beyond GWAS: microbiome and artificial intelligence as opportunities for precision medicine. *Camb Prisms Precis Med* 2023;1:e26. DOI
 18. Nakai M, Ribeiro RV, Stevens BR, et al. Essential hypertension is associated with changes in gut microbial metabolic pathways: a multisite analysis of ambulatory blood pressure. *Hypertension* 2021;78:804-15. DOI
 19. Pontarollo G, Kollar B, Mann A, et al. Commensal bacteria weaken the intestinal barrier by suppressing epithelial neuropilin-1 and Hedgehog signaling. *Nat Metab* 2023;5:1174-87. DOI PubMed PMC
 20. Lecuit M, Eloit M. Chapter 21 - The viruses of the gut microbiota. In: *The microbiota in gastrointestinal pathophysiology*. Elsevier; 2017. pp. 179-83. DOI
 21. Thursby E, Juge N. Introduction to the human gut microbiota. *Biochem J* 2017;474:1823-36. DOI PubMed PMC
 22. Beam A, Clinger E, Hao L. Effect of diet and dietary components on the composition of the gut microbiota. *Nutrients* 2021;13:2795. DOI PubMed PMC
 23. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. *BMJ* 2018;361:k2179. DOI PubMed PMC
 24. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. *Therap Adv Gastroenterol* 2013;6:295-308. DOI PubMed PMC
 25. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. *World J Gastroenterol* 2015;21:8787-803. DOI PubMed PMC
 26. Wu Y, Xu H, Tu X, Gao Z. The role of short-chain fatty acids of gut microbiota origin in hypertension. *Front Microbiol* 2021;12:730809. DOI PubMed PMC
 27. Chen XF, Ren SC, Tang G, Wu C, Chen X, Tang XQ. Short-chain fatty acids in blood pressure, friend or foe. *Chin Med J* 2021;134:2393-4. DOI PubMed PMC
 28. Miyamoto J, Kasubuchi M, Nakajima A, Irie J, Itoh H, Kimura I. The role of short-chain fatty acid on blood pressure regulation. *Curr Opin Nephrol Hypertens* 2016;25:379-83. DOI PubMed
 29. Huynh K. Microbial metabolites reduce SBP in patients with resistant hypertension. *Nat Rev Cardiol* 2023;20:140. DOI PubMed
 30. Deng W, Zhang L, Du Q, et al. The association of serum total bile acid with new-onset hypertension during pregnancy. *BMC Pregnancy Childbirth* 2022;22:879. DOI PubMed PMC
 31. Arab J, Barrera F, Arrese M. Bile acids and portal hypertension. *Ann Hepatol* 2017;16:S83-6. DOI PubMed
 32. O'Donnell JA, Zheng T, Meric G, Marques FZ. The gut microbiome and hypertension. *Nat Rev Nephrol* 2023;19:153-67. DOI PubMed
 33. Avery EG, Bartolomaeus H, Maifeld A, et al. The gut microbiome in hypertension: recent advances and future perspectives. *Circ Res* 2021;128:934-50. DOI
 34. Yan D, Sun Y, Zhou X, et al. Regulatory effect of gut microbes on blood pressure. *Animal Model Exp Med* 2022;5:513-31. DOI PubMed PMC
 35. Jose PA, Raj D. Gut microbiota in hypertension. *Curr Opin Nephrol Hypertens* 2015;24:403-9. DOI PubMed PMC
 36. Song JS, Kim JOR, Yoon SM, Kwon M, Ki C. The association between gut microbiome and hypertension varies according to enterotypes: a Korean study. *Front Microbiomes* 2023;2:1072059. DOI
 37. Zhang Y, Zheng T, Ma D, et al. Probiotics *Bifidobacterium lactis* M8 and *Lactobacillus rhamnosus* M9 prevent high blood pressure via modulating the gut microbiota composition and host metabolic products. *mSystems* 2023;8:e0033123. DOI PubMed PMC
 38. Cookson TA. Bacterial-induced blood pressure reduction: mechanisms for the treatment of hypertension via the gut. *Front Cardiovasc Med* 2021;8:721393. DOI PubMed PMC
 39. Hoyle L, Jiménez-Pranteda ML, Chilloux J, et al. Metabolic retroconversion of trimethylamine N-oxide and the gut microbiota. *Microbiome* 2018;6:73. DOI PubMed PMC
 40. Shanmugham M, Bellanger S, Leo CH. Gut-derived metabolite, trimethylamine-N-oxide (TMAO) in cardio-metabolic diseases: detection, mechanism, and potential therapeutics. *Pharmaceuticals* 2023;16:504. DOI PubMed PMC
 41. Huang R, Yan L, Lei Y. The gut microbial-derived metabolite trimethylamine N-oxide and atrial fibrillation: relationships, mechanisms, and therapeutic strategies. *Clin Interv Aging* 2021;16:1975-86. DOI PubMed PMC
 42. Yang S, Li X, Yang F, et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. *Front Pharmacol* 2019;10:1360. DOI PubMed PMC
 43. Khodor S, Reichert B, Shatat IF. The microbiome and blood pressure: can microbes regulate our blood pressure? *Front Pediatr* 2017;5:138. DOI PubMed PMC
 44. Masenga SK, Hamooya B, Hangoma J, et al. Recent advances in modulation of cardiovascular diseases by the gut microbiota. *J Hum Hypertens* 2022;36:952-9. DOI PubMed PMC
 45. Jama HA, Kaye DM, Marques FZ. The gut microbiota and blood pressure in experimental models. *Curr Opin Nephrol Hypertens* 2019;28:97-104. DOI PubMed
 46. Joe B, McCarthy CG, Edwards JM, et al. Microbiota introduced to germ-free rats restores vascular contractility and blood pressure. *Hypertension* 2020;76:1847-55. DOI PubMed PMC
 47. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. *Cell Res* 2020;30:492-506. DOI PubMed PMC

48. Krzemińska J, Wronka M, Młynarska E, Franczyk B, Rysz J. Arterial hypertension-oxidative stress and inflammation. *Antioxidants* 2022;11:172. DOI PubMed PMC
49. Ghatage T, Goyal SG, Dhar A, Bhat A. Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies. *Hypertens Res* 2021;44:740-55. DOI PubMed PMC
50. Prado NJ, Ramirez D, Mazzei L, et al. Anti-inflammatory, antioxidant, antihypertensive, and antiarrhythmic effect of indole-3-carbinol, a phytochemical derived from cruciferous vegetables. *Heliyon* 2022;8:e08989. DOI PubMed PMC
51. Tokarek J, Budny E, Saar M, et al. Does the composition of gut microbiota affect hypertension? *Int J Mol Sci* 2023;24:1377. DOI PubMed PMC
52. Sun D, Xiang H, Yan J, He L. Intestinal microbiota: a promising therapeutic target for hypertension. *Front Cardiovasc Med* 2022;9:970036. DOI PubMed PMC
53. Caspani G, Kennedy S, Foster JA, Swann J. Gut microbial metabolites in depression: understanding the biochemical mechanisms. *Microb Cell* 2019;6:454-81. DOI PubMed PMC
54. Parker A, Fonseca S, Carding SR. Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health. *Gut Microbes* 2020;11:135-57. DOI PubMed PMC
55. Zheng T, Marques FZ. Gut microbiota: friends or foes for blood pressure-lowering drugs. *Hypertension* 2022;79:1602-4. DOI PubMed
56. Chen HQ, Gong JY, Xing K, Liu MZ, Ren H, Luo JQ. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in antihypertensive treatment. *Front Med* 2021;8:742394. DOI PubMed PMC
57. Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. *Int J Hypertens* 2011;2011:236239. DOI PubMed PMC
58. Kyoung J, Atluri RR, Yang T. Resistance to antihypertensive drugs: is gut microbiota the missing link? *Hypertension* 2022;79:2138-47. DOI PubMed
59. Choi MS, Yu JS, Yoo HH, Kim DH. The role of gut microbiota in the pharmacokinetics of antihypertensive drugs. *Pharmacol Res* 2018;130:164-71. DOI PubMed
60. Qi Y, Aranda JM, Rodriguez V, Raizada MK, Pepine CJ. Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension - a case report. *Int J Cardiol* 2015;201:157-8. DOI PubMed PMC
61. Robles-Vera I, Toral M, de la Visitación N, et al. Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects. *Br J Pharmacol* 2020;177:2006-23. DOI PubMed PMC
62. Karbach SH, Schönfelder T, Brandão I, et al. Gut microbiota promote angiotensin II-induced arterial hypertension and vascular dysfunction. *J Am Heart Assoc* 2016;5. DOI PubMed PMC
63. Yang T, Aquino V, Lobaton GO, et al. Sustained captopril-induced reduction in blood pressure is associated with alterations in gut-brain axis in the spontaneously hypertensive rat. *J Am Heart Assoc* 2019;8:e010721. DOI PubMed PMC
64. Brocker CN, Velenosi T, Flaten HK, et al. Metabolomic profiling of metoprolol hypertension treatment reveals altered gut microbiota-derived urinary metabolites. *Hum Genomics* 2020;14:10. DOI PubMed PMC
65. Konop M, Radkowski M, Grochowska M, Perlejewski K, Samborowska E, Ufnal M. Enalapril decreases rat plasma concentration of TMAO, a gut bacteria-derived cardiovascular marker. *Biomarkers* 2018;23:380-5. DOI PubMed
66. Unger T, Borghi C, Charchar F, et al. 2020 international society of hypertension global hypertension practice guidelines. *Hypertension* 2020;75:1334-57. DOI PubMed
67. Davani-Davari D, Negahdaripour M, Karimzadeh I, et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. *Foods* 2019;8:92. DOI PubMed PMC
68. Jama HA, Rhys-Jones D, Nakai M, et al. Prebiotic intervention with HAMSAB in untreated essential hypertensive patients assessed in a phase II randomized trial. *Nat Cardiovasc Res* 2023;2:35-43. DOI
69. Streppel MT, Arends LR, van 't Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. *Arch Intern Med* 2005;165:150-6. DOI PubMed
70. Ansari F, Neshat M, Pourjafar H, Jafari SM, Samakkhah SA, Mirzakhani E. The role of probiotics and prebiotics in modulating of the gut-brain axis. *Front Nutr* 2023;10:1173660. DOI PubMed PMC
71. Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. *Hypertension* 2014;64:897-903. DOI PubMed
72. Qi D, Nie XL, Zhang JJ. The effect of probiotics supplementation on blood pressure: a systemic review and meta-analysis. *Lipids Health Dis* 2020;19:79. DOI PubMed PMC
73. Cardoso AM. Can changes in gut microbiota predict progression toward diabetes? *J Explor Res Pharmacol* 2021;6:168-9. DOI
74. Lagoumintzis G, Patrinos GP. Triangulating nutrigenomics, metabolomics and microbiomics toward personalized nutrition and healthy living. *Hum Genomics* 2023;17:109. DOI PubMed PMC